SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (Pink Sheets: MNTR) announced that it has entered into discussions with a private biotechnology company regarding a possible strategic relationship, including a possible merger. Consistent with Mentor’s strategic focus of investing in leading edge cancer immunotherapy companies, the biotechnology company is developing a targeted cancer immunotherapy, and is preparing to enter into late stage clinical trials.
